Alphatec spent its last report convincing investors that the first-quarter stumble in its EOS imaging business was a matter of execution rather than a crack in the story. The third-quarter release, due after the close on October 29, is where that argument has to start paying off in the numbers. Management has built a 2026 plan that leans heavily on the second half, and this quarter offers the first real look at whether the acceleration it promised is arriving on schedule.
The Street is looking for revenue of about $224.3 million, up roughly 14% from $196.5 million a year ago, along with an adjusted profit of 11 cents a share. The Earnings Whisper sits a bit lower at 9 cents, a modest gap that suggests the more cautious crowd is not counting on a big earnings beat. Given that the company's recent reported per-share results have been losses, adjusted EBITDA and cash flow are the cleaner profitability gauges here. On revenue, consensus for the full year of about $883 million is essentially on top of management's reaffirmed target of roughly $882 million, so analysts are not reaching beyond the company's own outlook. The math, however, is demanding. With about $406 million booked in the first half, the guide implies roughly $476 million in the back half, and if the third quarter lands near consensus, the fourth quarter would need to clear $250 million.
That is why the operating details matter more than the headline beat or miss. Management guided second-half surgical growth to accelerate to 18% from 17%, even while expecting case volume growth to cool from about 20% to the high teens. Squaring those two claims depends on revenue per case, which fell about 2.7% in the second quarter as mix, international sales and weak biologics attachment weighed on pricing. The company has lowered its per-case outlook twice this year, from low-single-digit growth to flat to a low-single-digit decline. A third quarter that shows stabilization would validate the plan, while another step down would raise doubts about how the surgical acceleration gets done. Surgeon user and case growth, which have run above 20% for several quarters, remain the best evidence that the adoption engine is still humming.
EOS is the other swing factor. Revenue recovered to $17 million in the second quarter from $14 million in the first, but the reduced $77 million full-year target still implies something like $23 million a quarter in the back half. Installations are lumpy, so investors should look for order commentary and backlog signals as much as the reported figure. The improved implant pull-through at EOS Insight accounts, now around a 32% lift within six months, is the strategic reason the imaging business matters to the spine franchise.
Profitability is where the last quarter genuinely impressed. Gross margin reached 72.5%, adjusted EBITDA margin hit 17%, and management raised its full-year EBITDA target to about $140 million. With roughly $57 million earned in the first half, the second half needs around $83 million, so continued operating leverage is required, not optional. Free cash flow of $4 million to $6 million, guided for the quarter, would extend a streak that underpins the balance-sheet improvement from the recent refinancing.
The market has already rewarded the turnaround in tone. Shares have gained about 10% since the last report while the S&P 500 slipped, and sentiment has moved from modestly bearish to neutral. Still, at $10.86 the stock sits just under its 200-day moving average and about 6% below its post-earnings high of $11.54, so it has not yet broken out. The central question is whether Alphatec can show surgical growth accelerating and margins expanding without revenue per case eroding further. If it can, the back-half-loaded year looks credible; if not, the recovery narrative will look more fragile than the stock currently implies.